Table 4.
Prevalence of the gut microbiota in the studied groups
| N (%) | Group I (n = 100) | Group II (n = 100) | OR (95% CI) | p |
|---|---|---|---|---|
| NAFLD patients | Healthy control | |||
| Total Eubacteria | 100 | 100 | NC | NC |
| Actinobacteria | - | - | - | - |
| Bifidobacterium spp. | 100 | 100 | NC | NC |
| Bacteroidetes | 100 | 100 | NC | NC |
| Bacteroides fragilis | 100 | 100 | ||
| Firmicutes | 100 | 100 | NC | NC |
| Clostridium difficile | 61 | 44 | 3.3 (1.06–8.4) | 0.01 |
| Clostridium perfringens | 38 | 64 | 1.8 (0.51–8.5) | 0.42 |
| Enterococcus faecalis | 16 | 13 | 0.41 (0.08–1.33) | 0.22 |
| Lactobacillus spp. | 100 | 100 | NC | NC |
| Staphylococcus aureus | 46 | 52 | 0.87 (0.41–2.08) | 0.68 |
| Proteobacteria | - | - | - | - |
| Escherichia coli | 100 | 100 | NC | NC |
| Salmonella spp. | 58 | 30 | 2.08 (0.82–5.9) | 0.02 |
| Euyarchaeota | - | - | - | - |
| Prevotella copri | 100 | 100 | NC | NC |
Chi-square tests
NC = not calculatedP significant < 0.05